Physician profile
Yan Duan
NPI 1649650045
$6,227.94
in general payments reported to CMS, 2019-2025
33 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $670 · 2021: $1,378 · 2022: $1,115 · 2023: $1,122 · 2024: $1,073 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,662 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,662.46 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,298.99 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $786.48 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amarin Pharma, INC. | $502.70 | 2019-2023 | |
| Pfizer INC. | $446.46 | 2020-2025 | |
| Novo Nordisk INC | $396.67 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $379.93 | 2021-2024 | |
| Eisai INC. | $246.78 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.07 | 2019-2025 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals Lp | $198.30 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $173.00 | 2022-2025 | Evenity, Prolia, Prolia |
| Allergan, INC. | $168.17 | 2019-2020 | |
| Astellas Pharma US INC | $150.89 | 2019-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company Ltd. | $142.19 | 2022 | |
| Glaxosmithkline, LLC. | $132.05 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceuticals, INC. | $123.92 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $117.78 | 2019-2023 | Belsomra |
| Nestle Healthcare Nutrition INC. | $95.91 | 2021 | |
| Radius Health, INC. | $83.10 | 2019-2024 | Tymlos |
| Otsuka America Pharmaceutical, INC. | $80.25 | 2023-2024 | Rexulti |
| Tandem Diabetes Care, INC. | $65.04 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Renalytix Ai, INC. | $62.48 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Exact Sciences Corporation | $54.66 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $49.29 | 2021 | |
| Genentech USA, INC. | $46.04 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.75 | 2024 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $44.75 | 2023-2024 | Gvoke Hypopen |
| Boston Scientific Corporation | $27.93 | 2025 | Watchman Access System |
| Amryt Pharma Holdings Ltd | $22.15 | 2022 | |
| Teleflex LLC | $21.38 | 2023 | Urolift |
| Abbott Laboratories | $20.65 | 2023 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $17.63 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $13.90 | 2022 | |
| Nabriva Therapeutics, Plc | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Duan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.